Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots available to read over the weekend!
https://www.amazon.com/Marijuana-Cannabinoids-Forensic-Science-Medicine/dp/1588294560/ref=sr_1_3?s=books&ie=UTF8&qid=1497106310&sr=1-3&refinements=p_27%3AMahmoud+A.+ElSohly
Sleeping well Holding NMUS
Is the Phase 2a study
Really just with oral dose of CBD?
Was reading it and I think that is all
Not a derivative?
Vinpat, is this our Dr. Murphy?
Aerosolized vancomycin for the
treatment of MRSA after lung
transplantation
DON HAYES JR BRIAN S. MURPHY
TIMOTHY W. MULLETT AND DAVID J. FEOLA
Preoperative decolonization of methicillin-resistant Staphylococcus aureus
by Larkin, Seth A; Murphy, Brian S
Do you know? Have a good weekend
CJ, I can't find it
Scholarly search of ElSohly's work....100+ articles....
I cannot Find the chart!
So who knows....maybe They dragged it from a Article that I can't find...or if it was Data shared privately with NMUS
I did find lots of Cool stuff through, digging
-
UMiss work from 1993
GLTFA
DYODD
For example:
Here is a journal article from the 90's
'Ag-THC Metabolites in Meconium: Identification of
11-OH-Ag-THC, 813,11-diOH-Ag-THC, and 11-nor-ASTHC-
9-COOH as Major Metabolites of A9-THC
Mahmoud A. EISohly and Shixia Feng
EISohly Laboratories, Incorporated (EL/), 5 Industrial Park Drive, Oxford, Mississippi 38655'
How does EISohly Laboratories, and the research that goes on there, relate to NMUS if at all?
If not, is EISohly Laboratories have deals with anyone? I noticed the two articles I have found so far were funded publicly through NIDA and different grants.
Nemus and Elsohly laboratories
Does NMUS have anything to do with it, or is separate from the work done at UmIss labs? I have seen some journal articles with data from El Sohly Labs to do with cannabis
How much time does ElSohly spend there compared to UMIss and NMUS?
Anyone know what goes on there?
Yes I agree With this. That chart is Not labeled NB1222 v. dronabinol, so I don't have a Problem with it.
It might Be from a public study and not 'internal data' or it could be different Umiss research never made public.
Still sleeping Quite well holding. GW slips under $100/sh....those will need a new place to reinvest :p
Ya, I know
But it is Kinda confusing. Nemus has had a exclusive agreement on UM4718, which is suppository dosage form containing Dronabinol Hemisuccinate and other esters, for a long time. But, a DMS was used in the original chart that NEMUS said they didn't license, and now the same chart is used but it says 'THC Prodrug'. The DMS is a THC pro-drug, it is just titled differently and Nemus no longer says they don't have the license to it.
Again, even though the data is possibly from here and out in the public:
https://www.ncbi.nlm.nih.gov/pubmed/27285147
https://www.researchgate.net/publication/21488661_Rectal_bioavailability_of_delta-9-tetrahydrocannabinol_from_various_esters
But Nemus says the chart is from 'Internal data'.
I imagine there are studies UMiss has done that have no been published unlike the above.
Some of them are probably to do with different formulations of the DMS/THC Pro drug.
Nemus is developing a DMS/THC pro drug.
I imagine UMiss has shared more of their research on their DMS/THC Pro drug's, including UM4718.
Nemus chose to use data from a formulation that is different from UM4718, but still a DMS/THC Prodrug. This is all in preparation for the development of NB1222.
Ask Vinpat why they did this, he is Much smarter than me
Ahh, now I see
In the 2015 presentation, the chart is used and reads 'DHS suppository* vs. Marinol and the * references that Nemus has not licensed the particular formulation used in the comparison.
See here:
I look forward to reading Vinpat posts
Like kids look forward to candy on Halloween
I think it is safe to say Mallinckrodt was the company ElSohly and UM were working with before Nemus on their CINV/THC indication. As far as why the deal is terminated, like Vinpat said, it could be for different reasons.
UofM and Elsohly have a very good deal with Nemus in terms of protecting their IP and ensuring they get Paid their fair Share if the indications make it to the market. Maybe Mallinckrodt didn't like the demands coupled with the risks associated with cannabinoids. But again, look at the agreements between UMiss and NMUS; locked in and exclusive. The window has closed on anyone else getting their hands on the IP and doing something with it. Wouldn't be a bad question to ask IR and confirm this though....
CJ, I like your Style. You ask Tough questions like Vinpat. But, I think it is harsh to say NMUS is misrepresenting the data on their THC prodrug suppository for CINV. I am sure more research has occurred over the period of time between the Mallinckrodt deal and present day. It might of built off earlier work, and set similar metrics to measure efficacy, but your making it sound like they Copy and Pasted 10-20 year old studies and called them 'internal data'....
Here are the researchers that discovered MRSA killing effect --> https://www.technologyreview.com/s/410815/a-new-mrsa-defense/
One thing to find Something, another thing to Know what to do With it
Vinpat, I am going to look for those Phase III studies where the psychoactive effects killed the candidate...
Thanks to wOLF OF Weed for the Pump, right?>
Anyone noticing a pattern with him.....IMLFF...VNNYF
Nemus and Catalent
'Nemus has subsequently contracted with Catalent Pharma Solutions (Catalent) to begin formulation work associated with NB2111, the candidate product for managing chemotherapy-induced nausea and vomiting (CINV).'
this is from a PR Dec 2016
I can't find anything about Catalent in latest 10Q
'In its fiscal year 2014 (ending June 30), Catalent’s customers included 83 of the top 100 branded drug marketers, 20 of the top 25 generics marketers, 38 of the top 50 biologics marketers, and 19 of the top 20 consumer health marketers globally.[citation needed] On July 31, 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).'
Catalent provides all the services related to drug development EXCEPT commercialization and marketing? They will help formulate, manufacture and navigate regulatory pathways but Nemus will need someone else to partner with still to sell the drug?
Thanks
*chills*
GLTFA
DYODD
'In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. '
'On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery.'
'On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, a pro-drug formulation of cannabidiol ("CBD") for products administered through each of ocular or rectal delivery. '
'On January 10, 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases.'
Don't think this is happening anymore, CJ 'I know Elsohly is extracting THC to sell to Mallinckrodt to manufacture generic dronabinol'
'NEMUS"is"the"sole!development!and!commercializaion!partner!of!the!University!of!
Mississippi,'
If a cannnibinoid drug is being developed from UMiss, NEMUS gets some of the juice for sure.
Thanks to CJ for making me dig
http://www.alternet.org/story/141522/is_big_pharma_trying_to_take_all_the_fun_out_of_pot
Article dated 2009
NEMUS created in 2011 (I think) and public went late 2014/2015.
Would guess the time has come and gone for Mallin and ElSohly. Mallin makes Cesamet. I went to see what Cesamet was about, and found something interesting.
'Although Cesamet was initially approved by the FDA in 1985, it was later withdrawn from the market by then-manufacturer Eli Lilly for commercial reasons. The drug has been marketed as an anti-nauseant in Canada and the United Kingdom by Valeant Pharmaceuticals, which purchased the rights to Cesamet in 2004. According to the manufacturer, potential adverse reactions to the drug include ataxia (loss of ability to coordinate muscular movement), euphoria, headache, vertigo, increased heart rate, and concentration difficulties.'
Dr. Murphy was the CSO at Valeant 2003-2006 before Pearson showed up. Valeant acquired Cesamet in 2004.
I always thought Murphy was just a smart guy who saw an opportunity with cannibinoids, but didn't have any experience.
Vinpat, Has he been at this for longer than I thought?
Well, Nemus has perpetual rights to a lot of UMiss IP and is their exclusive partner. Maybe that is why the partnership fell apart.
Can I get the links to the Elsohly interview you are referencing? How long ago was it?
There is a somewhat detailed presentation on it in the PP I linked to.
Also, why not given them 5-10% of the global market when discounting their cash flows? MRSA seems completed, all these different strains, won't there be more than one medication used for the next while? Nothing seems to be a cure all...
You need to Check your facts and make sure to do your homework
'NEMUS proprietary cannabinoid cocktails exert!significant killing
power against!mulMple species!of MRSA with in vitro experiments!
demonstrating FIC data consistently 0.3'
Ludgunin, more a prevention than a cure right?
The UV far light seems cool, but they say not a cure all for surgical infections? Vinpat says their MRSA candidate is strong
First the warning was 3 months
Now it is 2-3 months....
I'm thinking about the next 2-3 years Chico, not the next 2 to 3 months
Have a good Weekend to you Sir
Drink some Tequila Despacito!
I used to own Kalytera
I can't exactly remember the dates, but I took a starter position at .60c CAD. I averaged down at .40c CAD and than sold the entire position at .35c CAD. So, probably biased a bit because I took a nice loss.
I got rid of my position for a number of reasons, but mainly because of Thesis Creep which is DEADLY
Why did I first purchase Kaly? First, I was told diversification is good. I wanted exposure to the cannabis drug development space and Alpha. So I purchased shares in a number of names including Kaly, none of which I own now.
Second, Kaly has Dr. Mech the godfather of cannabis on their Sci board. Their pipeline targeted pain related to osteoporosis and other inflammation related ailments. I am aware that a solid body of evidence for CBD treatment of pain and inflammation exists. Salzman and Ferrel also seemed to have good records, so I hit the ask.
FYI, Salzman their COO or whatever doesn't even own any shares of Kaly.
Also, Aphria purchased a lot of shares so I believed they knew what they were doing (I don't think they do anymore).
Why did I Get out and Fast? First, the Thesis changed when they bought Talent Biotechs from Israel. All of a sudden their lead candidate was GvHD and their were a some new people involved I knew nothing about. If their pain indications were good, why spend 10m USD and dilute shareholders to acquire a new indication (albeit one in Phase 2 studies).
Second, the Anson fund. I have Nothing against short-biased funds. They are critical for markets. People can DYODD, but I didn't like what I found about them. It appears a former associate(s) of Anson obtained confidential FBI documents about an ongoing investigation into a company. Instead of notifying the authorities about the leak, they took a short position on the company and made the documents public. Some of the accused were convicted and are serving jail time. I like guys with Spikes, but that is Bottom of the Barrel stuff.
Third, David Stefansky. The co-founder, now EX board chair, has been sued for 'death-spiral' PIPE financing. Basically, providing financing which can be converted into equity at anytime (at whatever current market price). He took a short position against this company, putting pressure on the Stock Price, and than attempted to convert the debt to equity. What that Whacko chico was accusing Schneider of doing with Nemus (even though we proved him wrong). The judge ruled in favor of Stefansy, but admitted that while what he did wasn't legal, his behavior was clearly Not in the companies best interest. The company eventually went bankrupt.
That's when I discovered Stefansky led a PIPE for Kaly's RTO shell at .10c weeks before the RTO occured. He still has 3.5 shares of Kly, but I'd like to know how much he had at the start. Anything goes in Canada I guess....
The Dr. Mech connection became less important too. I watched a lecture where he referenced different cannabinoid molecules he was developing with other researchers; one did have a label 'KALY###' but there were others that had nothing to do with KALY. That is when I discovered he is on the board at other cannabinoid companies. TRPX is one. He also just retired apparently.
They have 3m in cash, they are applying for a 5m grant in Israel. I don't see how they bring candidates to the market without further dilution. From a valuation perspective, they do appear to be very cheap when compared to other micro cap Canadian listed cannabinoid companies. But given the people that are involved, and how much the original Thesis had changed, I took my Beating and moved on.
As far as how many names you want to hold in the cannabis space, and which sub-sectors (bio-tech, Medical cannabis producers, rec cannabis producers), you have to decide for yourself. For me, I like the Druckenmiller style of where if you have conviction in an idea, then you can get enough!
DYODD and GLTFA
*will it start trading again?
What about Finore? You know, the guys who used the same financing scam guys at Core Capital for their private placements?
Did that placement at .50c USD close yet?
CJ, can you enlighten us as to the current efficacy and outlook for the non-cannibinoid MrSA targets you mentioned?
I would go read about what Vinpat has said about GMP medical growers.
If your looking for exposure to rec market, good luck to you
I guess it depends on what you are looking to achieve with investing in NMUS. If your looking to flip .20's and .30's if it gets to .60-70, maybe that does happen in the next few months. It could also tread water for the same time period. I'm not really to concerned about that.
If you have locked in your capital for the next 12-36 months, depending on when milestones are achieved, you are looking for a lot more than a stock price in the pennies. GW has a lead candidate with a potential 4m global market that has very little competition and 350m in cash. NMUS has a lead candidate with a potential global market of 2m with a lot competition and 20m in cash. GW has a market cap on 2.7b, and Goldman Sachs has valued the company at 7-8b if it was to be taken over. NMUS has a market cap of 30m....
This is a serous arbitrage opportunity IMO. But, to justify risk involved with NMUS, the return needs to be substantial.
To give you an idea, lets say NMUS is able to make NB1111 and get it to the market. No licensing deal, to make this example simple. NB1111 is relatively successful, getting 5% of the global market wich equals 100m in annual earnings. Pharma biotechs usually trade a EV/EBITDA multiple of 11.5x.
(http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/vebitda.html)
So in this scenario, NMUS should have a EV just north of a billion. Currently their EV is 10m.
WARNING: Crude valuation. should not be used for investment purposes
DYODD
GLTFA
I got hurt. Stay away, cashless warrants. Google David stefansky, didnt like what I found. Anson fund, who is short biased, is the biggest holder. Also found not great things about them.
They did a PIPE as Santa Maria Petroleum right before the RTO at .10c CAD. A week later, boom Kalytera born....low energy
Where is the cash to bring the pipeline to fruition?
I don't see what could happen in the next few weeks that could act as a catalyst for SP appreciation....
Q4 is when the CINV trials could start, and whether it qualifies for the 5052b pathway.
Q1-2 is when NB1111 trials could start, and it is possible a licensing deal/partnership is announced before then.
Might be a quiet summer, but I am sure lots going on behind the scenes.
Remember though....
'Getting CanacCORNED $IMLFF $IN.c -unlike Placements this financing is a prospectus offering = free trading.'
With what is going at Cannacord with Cannabis Wheaton, I wouldn't be super happy with how involved they are with IMLFF
Why don't you explain how it works then, CJ?
Look at their pipeline from 2015 and look at it now
Thesis Creep is Deadly
GLTFA
I don't think that is what Vinpat is saying. I think he means that Schneider has more concrete information in regards to items already made public by the CEO. I.e they have already stated (for some time) that they have been attempting to reach a licensing deal for NB1111. Schneider, through the process of the placement and doing their own DD, likely obtained information about the viability and structure of a deal. Having the resources and capital to do that is what affords that advantage.
Vinpat's 50x, or 5000%, might look a little silly but check my thread comparing the market caps and enterprise values of the industry. NMUS has a EV of 11m USD. CARA is 495m and GW is 2422m. NMUS is way behind in advancing their pipeline compared to those two, but the only thing stopping them was acquiring capital that didn't destroy shareholder value. Their IP is as impressive as anyone in the sector IMO. So Vinpat's 50x isn't that far-fetched given a long enough timeline...
But i thought markets were efficient! :P